Dr Ali on the Need for Novel Targets Beyond BCMA in Multiple Myeloma Dr Awan on the Impact of CAR T-Cell Therapy on the CLL Treatment Paradigm Dr Lamba on Rapid Long-Read Epigenomic Diagnosis and Prognosis in AML Dr Montero on Zanidatamab and Evorpacept in HER2-Expressing Metastatic Breast...
Dr Ali on the S0221 Trial of Alternative Chemo Dosing Schedules in Breast Cancer Dr Rugo on Elacestrant-Based Combinations in ER+/HER2– Metastatic Breast Cancer Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER+ Breast Cancer ...
Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer Unveiling the Latest in HER2+ Breast Cancer and Beyond With Drs Sara Hurvitz and Neil Iyengar Dr Ali on the S0221 Trial of Alternative Chemo Dosing Schedules in Breast Cancer...
Dr. Alice Y. Ho is a Radiation Oncologist in New York, NY. Find Dr. Ho's address, insurance information, hospital affiliations and more.
Dr Kim on The Efficacy and Safety of Odronextamab in R/R MZL Dr Goldsberry on the Risk of Secondary Malignancies With PARP Inhibitors in Ovarian Cancer Dr Ali on the Need for Novel Targets Beyond BCMA in Multiple Myeloma
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, discusses efficacy and safety findings from the phase 1 CHRYSALIS-2 trial (NCT04077463) evaluating amivantamab-vmjw (Rybrevant) in combination with laze...
Dr Ali on the Need for Novel Targets Beyond BCMA in Multiple Myeloma Dr Awan on the Impact of CAR T-Cell Therapy on the CLL Treatment Paradigm Dr Lamba on Rapid Long-Read Epigenomic Diagnosis and Prognosis in AML Dr Montero on Zanidatamab and Evorpacept in HER2-Expressing Metastatic...
Dr Ali on the Need for Novel Targets Beyond BCMA in Multiple Myeloma Dr Awan on the Impact of CAR T-Cell Therapy on the CLL Treatment Paradigm Dr Lamba on Rapid Long-Read Epigenomic Diagnosis and Prognosis in AML Dr Montero on Zanidatamab and Evorpacept in HER2-Expressing Metastatic Breast...
Noopur S. Raje, MD, professor of medicine at Harvard Medical School and director of the Multiple Myeloma Program at Massachusetts General Hospital, discusses recent findings with melflufen in relapsed/refractory multiple myeloma. Melflufen is a novel alkylating agent with less toxicity, says Raje. ...
Dr Ali on the S0221 Trial of Alternative Chemo Dosing Schedules in Breast Cancer Sharing the Latest in Breast Cancer Care With Drs Rena Callahan and Jame Abraham Dr Rugo on Elacestrant-Based Combinations in ER+/HER2– Metastatic Breast Cancer ...